Vyant Bio (VYNT) Reports Q1 Loss from Cont. Operations of $0.15

Vyant Bio (NASDAQ: VYNT) reported Q1 EPS from continuing operations of ($0.15), versus the consensus of ($0.16). Revenue for the quarter came in at $303 thousand versus the consensus estimate of $300 thousand.

Cash and cash equivalents totaled $16.4 million as of March 31, 2022.

For earnings history and earnings-related data on Vyant Bio (VYNT) click here.

You May Also Be Interested In

• Ackman adds Netflix, Visa and Mastercard in portfolio revamp
• Melco Resorts & Entertainment (MLCO) Misses Q2 EPS by 7c
• Studio City International Holdings Limited (MSC) Reports Q2 Loss of $0.02